Back to search

Aristotle University Of Thessaloniki (AUTH)

Σύνθεση υβριδικών ενώσεων στη στοχευμένη θεραπεία για τον καρκίνο

Abstract

dc:description

The integrin ανβ3 and the VEGF receptor represent crucial targets in the realm of targeted drug delivery due to their frequent overexpression or mutation in various cancer types. These receptors are intricately intertwined within cellular signalling pathways, where the activation of one pathway can significantly influence the behaviour of the other. The strategic design and synthesis of complicated hybrid compounds, tailored to modulate these signalling pathways hold the potential to create new anticancer therapeutics characterized by exceptional pharmacokinetic and pharmacodynamic attributes. This doctoral dissertation endeavours to elucidate the synthesis methodologies, biochemical analyses, computational modelling, and biological evaluations of novel hybrid compounds that target the ανβ3 integrin and VEGFR pathways. These hybrid molecules include the combination of angiogenesis inhibitors with the RGD peptide, antimetabolites, and moieties capable of inducing targeted degradation. In the first chapter, the synthesis of two peptide conjugates of the first-generation SRPK1 kinase inhibitor, SRPIN803, with the pentapeptide c(RGDyK), is presented. This chapter centers on the intricacies involved in merging SRPIN803 with other biologically active molecules, a challenge exacerbated by its phenolic terminus. Additionally, solid-phase peptide synthesis (SPPS) of c(RGDyK) starting from protected amino acids is developed. Finally, the computational and preclinical results of the compounds are presented, highlighting their anti-angiogenic potential. In the second chapter, the complete synthesis of the second-generation nanomolar SRPK1 inhibitor, JH-VII-139-1, is developed. The chapter includes the synthesis of three conjugates of JH-VII-139-1 with c(RGDyK), followed by the determination of the most stable among these conjugates. Subsequently, the synthesis of a trifunctional analogue carrying the fluorescent compound fluorescein is undertaken. This is followed by the revelation of cellular uptake of the peptide-drug conjugates of c(RGDyK) through fluorescence imaging. In the third chapter, hybrid compounds of angiogenesis inhibitors SRPIN803 and JH-VII-139-1 with antimetabolites such as gemcitabine, fluorouracil, and methotrexate are presented. The conjugation of the most potent inhibitor JH-VII-139-1 with three compounds inducing proteolysis, namely YTK-105, pomalidomide, and Boc3Arg, is then developed. Different conjugation techniques using cleavable and stable linkers are examined, as well as their contribution to the overall activity of the conjugates.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Leonidis, Georgios
  • Λεονίδης, Γεώργιος

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/56221

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Leonidis, Georgios; Λεονίδης, Γεώργιος. Σύνθεση υβριδικών ενώσεων στη στοχευμένη θεραπεία για τον καρκίνο. Aristotle University Of Thessaloniki (AUTH), 2023. http://hdl.handle.net/10442/hedi/56221